Neumora Therapeutics (NMRA) Return on Capital Employed [ROCE] (2023 - 2026)
Neumora Therapeutics' Return on Capital Employed [ROCE] was -188.96% in Q2 2026, down 68.24 percentage points from -120.72% a year earlier and down 32.24 percentage points from the prior quarter.
Powered by 
Analysis
Neumora Therapeutics (NMRA) Return on Capital Employed [ROCE] (2023 - 2026) Analysis & Trends
For FY2025, Return on Capital Employed [ROCE] at Neumora Therapeutics came in at -108.85%, down 38.90 percentage points from FY2024.
- In earlier years, Return on Capital Employed [ROCE] was -69.94% in FY2024 (-12.13 pp) and -57.81% in FY2023.
- The Q2 2026 figure marks the lowest quarterly Return on Capital Employed [ROCE] in data going back to Q4 2023.
- Compared with a year earlier, Return on Capital Employed [ROCE] has declined for seven straight quarters, with an average year-over-year change of -52.76 percentage points over the last seven quarters.
- Per Business Quant data, NMRA's Return on Capital Employed [ROCE] in the three quarters before Q2 2026 was -156.72% (Q1 2026), -158.67% (Q4 2025) and -140.35% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 35.41% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 17.52% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 21.60% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 4.65% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 9.91% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 17.37% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | -6.15% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 11.32% |
| 10 | Neumora Therapeutics | 88.31 Mn | -529.65 Mn | - | -188.96% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -188.96% |
| Mar 31, 2026 | -156.72% |
| Dec 31, 2025 | -158.67% |
| Sep 30, 2025 | -140.35% |
| Jun 30, 2025 | -120.72% |
| Mar 31, 2025 | -106.13% |
| Dec 31, 2024 | -86.42% |
| Sep 30, 2024 | -90.71% |
| Jun 30, 2024 | -72.92% |
| Mar 31, 2024 | -60.86% |
| Dec 31, 2023 | -50.89% |
API Access
Neumora Therapeutics Return on Capital Employed [ROCE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=NMRA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-capital-employed-[roce]", "ticker": "NMRA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=NMRA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();